DSGN
Design TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Positive clinical updates or faster-than-expected enrollment for one or more GeneTAC programs materially de-risk development and lead analysts to re-rate toward the high-teens price targets, driven by optionality value and limited float.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -13.8.
What can break
Clinical enrollment or readout delays
Momentum
81
Value
41
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $18.00 · Bear $7.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $21.00
Why
Momentum81 · Δ7d -13.8
Value41 · Δ7d +0.0
Sentiment57 · Δ7d +14.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
81
26% active weight
Current posture
7d trendSoftening
Δ7d
-13.8
Δ21d
+5.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
57
34% active weight
Current posture
7d trendImproving
Δ7d
+14.8
Δ21d
+4.3
Why this grade
Composite grade B. Momentum 80.8 / Value 41.1 / Sentiment 57.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$741.36M
Beta
1.64
Shares Out
62.46M
P/E (TTM) · Derived
-9.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.86
Rev YoY
-
EPS YoY
-8.0%
Gross Margin
-
Op Margin
-
Net Debt
-$218.31M
Current Ratio
22.28
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology